Limdi NA - Search Results

1

Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

Shendre A, Dillon C, Limdi NA. Shendre A, et al. Among authors: limdi na. Pharmacogenomics. 2018 Nov;19(17):1357-1371. doi: 10.2217/pgs-2018-0146. Epub 2018 Oct 22. Pharmacogenomics. 2018. PMID: 30345882 Free PMC article. Review.

2

Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.

Limdi NA, Beasley TM, Allison DB, Rivers CA, Acton RT. Limdi NA, et al. Blood Cells Mol Dis. 2006 Sep-Oct;37(2):100-6. doi: 10.1016/j.bcmd.2006.06.003. Epub 2006 Aug 2. Blood Cells Mol Dis. 2006. PMID: 16889993 Free PMC article.

3

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT. Limdi NA, et al. Clin Pharmacol Ther. 2008 Feb;83(2):312-21. doi: 10.1038/sj.clpt.6100290. Epub 2007 Jul 25. Clin Pharmacol Ther. 2008. PMID: 17653141 Free PMC article. Clinical Trial.

4

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT. Limdi NA, et al. Pharmacogenomics. 2008 May;9(5):511-26. doi: 10.2217/14622416.9.5.511. Pharmacogenomics. 2008. PMID: 18466099 Free PMC article.

5

Warfarin pharmacogenetics.

Limdi NA, Veenstra DL. Limdi NA, et al. Pharmacotherapy. 2008 Sep;28(9):1084-97. doi: 10.1592/phco.28.9.1084. Pharmacotherapy. 2008. PMID: 18752379 Free PMC article. Review.

6

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.

Schelleman H, Limdi NA, Kimmel SE. Schelleman H, et al. Among authors: limdi na. Pharmacogenomics. 2008 Sep;9(9):1331-46. doi: 10.2217/14622416.9.9.1331. Pharmacogenomics. 2008. PMID: 18781859 Review.

7

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N. Limdi NA, et al. Pharmacogenomics. 2008 Oct;9(10):1445-58. doi: 10.2217/14622416.9.10.1445. Pharmacogenomics. 2008. PMID: 18855533 Free PMC article.

8

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM. Limdi NA, et al. Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17. Blood Cells Mol Dis. 2009. PMID: 19297219 Free PMC article.

9

Expectations, validity, and reality in pharmacogenetics.

Limdi NA, Veenstra DL. Limdi NA, et al. J Clin Epidemiol. 2010 Sep;63(9):960-9. doi: 10.1016/j.jclinepi.2009.09.006. Epub 2009 Dec 7. J Clin Epidemiol. 2010. PMID: 19995676 Free PMC article. Review.

10

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium. Limdi NA, et al. Blood. 2010 May 6;115(18):3827-34. doi: 10.1182/blood-2009-12-255992. Epub 2010 Mar 4. Blood. 2010. PMID: 20203262 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

128 results

Search Page